The Food and Drug Administration (FDA) has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD), which can occur after stem cell or bone marrow transplants. The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.
FDA has approved a new form of asparaginase called Rylaze. The drug was developed to help alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia (ALL).
Clinical Trials Information for Patients and Caregivers
What Are Clinical Trial Endpoints?
In clinical trials, an endpoint is an event or outcome that can be measured to determine whether the intervention being studied is beneficial. To learn more about clinical trial endpoints, check out these terms from the NCI Dictionary of Cancer Terms.
This phase 2 trial will test a combination of trametinib (Mekinist) and hydroxychloroquine (Plaquenil) for people with bile duct cancer that has a mutated KRAS gene and has not responded to prior treatment. Doctors want to see if these drugs can lengthen the time it takes for the cancer to get worse.
This phase 1/2 trial will evaluate the combination of lurbinectedin (Zepzelca) and berzosertib in people with small cell lung cancer (SCLC) or high-grade neuroendocrine cancers. Lurbinectedin is FDA approved for SCLC that has spread. And berzosertib is an experimental drug that targets a protein that may help neuroendocrine cancers resist chemotherapy. Doctors will assess the safety of the combination and determine the maximum dose. They also want to see if the drugs cause tumors to shrink when given together.
This phase 1/2 trial will test the safety and tolerability of adding the radioactive drug radium-223 to olaparib (Lynparza) for people with castration-resistant prostate cancer that has spread to the bones. Olaparib targets a protein that helps cancer cells survive. And radium-223 accumulates in areas of the bone with cancer in them, delivering low levels of radiation to the area. Doctors want to see if these drugs can lengthen the time it takes for the cancer to get worse.
